Original from: Genomeweb
LumiraDx said on Wednesday that it has received CE marking for a molecular SARS-CoV-2 test and an assay that tests for both SARS-CoV-2 and influenza virus.
The Dual-Target SARS-CoV-2 STAR Complete test detects two gene markers to identify the presence of SARS-CoV-2, according to the company. The LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete assay allows for the simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2.
Both tests use LumiraDx's qSTAR single-step nucleic acid extraction and amplification technology and run on open RT-PCR instruments. Results are provided within 20 minutes.
Last month, London-based LumiraDx reported an 18 percent increase in first quarter revenues on strong sales of its COVID-19 testing products.
Source: LumiraDx Gets CE Marks for SARS-CoV-2 Test, COVID-19-Flu Assay
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.